| [1] |
Singh T, Fatehi Hassanabad M, Fatehi Hassanabad A. Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2):188636.
doi: 10.1016/j.bbcan.2021.188636
URL
|
| [2] |
Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer[J]. Lancet, 2021, 398(10299):535-554.
doi: 10.1016/S0140-6736(21)00312-3
URL
|
| [3] |
Suzuki T. Regulation of the intestinal barrier by nutrients: The role of tight junctions[J]. Anim Sci J, 2020, 91(1):e13357.
|
| [4] |
Otani T, Furuse M. Tight junction structure and function revisited[J]. Trends Cell Biol, 2020, 30(10):805-817.
doi: 10.1016/j.tcb.2020.08.004
URL
|
| [5] |
Piontek J, Krug SM, Protze J, et al. Molecular architecture and assembly of the tight junction backbone[J]. Biochim Biophys Acta Biomembr, 2020, 1862(7):183279.
doi: 10.1016/j.bbamem.2020.183279
URL
|
| [6] |
Gowrikumar S, Singh AB, Dhawan P. Role of claudin proteins in regulating cancer stem cells and chemoresistance-potential implication in disease prognosis and therapy[J]. Int J Mol Sci, 2019, 21(1):53.
doi: 10.3390/ijms21010053
URL
|
| [7] |
Popova OP, Kuznetsova AV, Bogomazova SY, et al. Claudins as biomarkers of differential diagnosis and prognosis of tumors[J]. J Cancer Res Clin Oncol, 2021, 147(10):2803-2817.
doi: 10.1007/s00432-021-03725-0
pmid: 34241653
|
| [8] |
Bhat AA, Syed N, Therachiyil L, et al. Claudin-1, a double-edged sword in cancer[J]. Int J Mol Sci, 2020, 21(2):569.
doi: 10.3390/ijms21020569
URL
|
| [9] |
Kolchakova D, Moten D, Batsalova T, et al. Tight junction protein claudin-12 is involved in cell migration during metastasis[J]. Biomolecules, 2021, 11(5):636.
doi: 10.3390/biom11050636
URL
|
| [10] |
Du H, Yang X, Fan J, et al. Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review)[J]. Mol Med Rep, 2021, 24(3):677.
doi: 10.3892/mmr.2021.12316
URL
|
| [11] |
Osanai M, Takasawa A, Murata M, et al. Claudins in cancer: Bench to bedside[J]. Pflugers Arch, 2017, 469(1):55-67.
doi: 10.1007/s00424-016-1877-7
URL
|
| [12] |
Lv J, Sun B, Mai Z, et al. CLDN-1 promoted the epithelial to migration and mesenchymal transition (EMT) in human bronchial epithelial cells via Notch pathway[J]. Mol Cell Biochem, 2017, 432(1-2):91-98.
doi: 10.1007/s11010-017-3000-6
URL
|
| [13] |
Chao YC, Pan SH, Yang SC, et al. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma[J]. Am J Respir Crit Care Med, 2009, 179(2):123-133.
doi: 10.1164/rccm.200803-456OC
URL
|
| [14] |
Merikallio H, Kaarteenaho R, Pääkkö P, et al. Impact of smoking on the expression of claudins in lung carcinoma[J]. Eur J Cancer, 2011, 47(4):620-630.
doi: 10.1016/j.ejca.2010.10.017
pmid: 21106366
|
| [15] |
Zhang Z, Wang A, Sun B, et al. Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma[J]. J Cardiothorac Surg, 2013, 8:95.
doi: 10.1186/1749-8090-8-95
URL
|
| [16] |
Wu JE, Wu YY, Tung CH, et al. DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression[J]. Theranostics, 2020, 10(19):8903-8923.
doi: 10.7150/thno.45785
URL
|
| [17] |
Pyo JS, Kim NY, Cho WJ. Prognostic role of claudin-1 immunohistochemistry in malignant solid tumors: A meta-analysis[J]. J Pathol Transl Med, 2019, 53(3):173-179.
doi: 10.4132/jptm.2019.02.03
URL
|
| [18] |
Sun BS, Yao YQ, Pei BX, et al. Claudin-1 correlates with poor prognosis in lung adenocarcinoma[J]. Thorac Cancer, 2016, 7(5):556-563.
doi: 10.1111/1759-7714.12368
URL
|
| [19] |
Ma L, Yin W, Ma H, et al. Targeting claudin-3 suppresses stem cell-like phenotype in nonsquamous non-small-cell lung carcinoma[J]. Lung Cancer Manag, 2019, 8(1):LMT04.
doi: 10.2217/lmt-2018-0010
URL
|
| [20] |
Che J, Yang Y, Xiao J, et al. Decreased expression of claudin-3 is associated with a poor prognosis and EMT in completely resected squamous cell lung carcinoma[J]. Tumour Biol, 2015, 36(8):6559-6568.
doi: 10.1007/s13277-015-3350-1
URL
|
| [21] |
Che J, Yue D, Zhang B, et al. Claudin-3 inhibits lung squamous cell carcinoma cell epithelial-mesenchymal transition and invasion via suppression of the Wnt/β-catenin signaling pathway[J]. Int J Med Sci, 2018, 15(4):339-351.
doi: 10.7150/ijms.22927
URL
|
| [22] |
Zhang L, Wang Y, Zhang B, et al. Claudin-3 expression increases the malignant potential of lung adenocarcinoma cells: Role of epidermal growth factor receptor activation[J]. Oncotarget, 2017, 8(14):23033-23047.
doi: 10.18632/oncotarget.14974
URL
|
| [23] |
Qu H, Qi D, Wang X, et al. CLDN6 suppresses c-MYC-mediated aerobic glycolysis to inhibit proliferation by TAZ in breast cancer[J]. Int J Mol Sci, 2021, 23(1):129.
doi: 10.3390/ijms23010129
URL
|
| [24] |
Qu H, Jin Q, Quan C. CLDN6: From traditional barrier function to emerging roles in cancers[J]. Int J Mol Sci, 2021, 22(24):13416.
doi: 10.3390/ijms222413416
URL
|
| [25] |
Kojima M, Sugimoto K, Tanaka M, et al. Prognostic significance of aberrant claudin-6 expression in endometrial cancer[J]. Cancers (Basel), 2020, 12(10):2748.
doi: 10.3390/cancers12102748
URL
|
| [26] |
Reinhard K, Rengstl B, Oehm P, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors[J]. Science, 2020, 367(6476):446-453.
doi: 10.1126/science.aay5967
URL
|
| [27] |
Micke P, Mattsson JS, Edlund K, et al. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer[J]. Int J Cancer, 2014, 135(9):2206-2214.
doi: 10.1002/ijc.28857
URL
|
| [28] |
Zhang C, Guo C, Li Y, et al. Identification of claudin-6 as a molecular biomarker in pan-cancer through multiple omics integrative analysis[J]. Front Cell Dev Biol, 2021, 9:726656.
doi: 10.3389/fcell.2021.726656
URL
|
| [29] |
Wang Q, Zhang Y, Zhang T, et al. Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer[J]. Onco Targets Ther, 2015, 8:1971-1977.
|
| [30] |
Wang K, Xu C, Li W, et al. Emerging clinical significance of claudin-7 in colorectal cancer: A review[J]. Cancer Manag Res, 2018, 10:3741-3752.
doi: 10.2147/CMAR.S175383
pmid: 30288105
|
| [31] |
Akizuki R, Shimobaba S, Matsunaga T, et al. Claudin-5, -7, and -18 suppress proliferation mediated by inhibition of phosphorylation of Akt in human lung squamous cell carcinoma[J]. Biochim Biophys Acta Mol Cell Res, 2017, 1864(2):293-302.
doi: 10.1016/j.bbamcr.2016.11.018
URL
|
| [32] |
Lu Z, Kim DH, Fan J, et al. A non-tight junction function of claudin-7-Interaction with integrin signaling in suppressing lung cancer cell proliferation and detachment[J]. Mol Cancer, 2015, 14:120.
doi: 10.1186/s12943-015-0387-0
URL
|
| [33] |
Kim DH, Lu Q, Chen YH. Claudin-7 modulates cell-matrix adhesion that controls cell migration, invasion and attachment of human HCC827 lung cancer cells[J]. Oncol Lett, 2019, 17(3):2890-2896.
|
| [34] |
Zheng Z, Lin K, Hu Y, et al. Sulforaphane metabolites inhibit migration and invasion via microtubule-mediated Claudins dysfunction or inhibition of autolysosome formation in human non-small cell lung cancer cells[J]. Cell Death Dis, 2019, 10(4):259.
doi: 10.1038/s41419-019-1489-1
URL
|
| [35] |
Lu Z, Liu Y, Xu J, et al. Immunohistochemical quantification of expression of a tight junction protein, claudin-7, in human lung cancer samples using digital image analysis method[J]. Comput Methods Programs Biomed, 2018, 155:179-187.
doi: 10.1016/j.cmpb.2017.12.014
URL
|
| [36] |
Kyuno D, Takasawa A, Kikuchi S, et al. Role of tight junctions in the epithelial-to-mesenchymal transition of cancer cells[J]. Biochim Biophys Acta Biomembr, 2021, 1863(3):183503.
doi: 10.1016/j.bbamem.2020.183503
URL
|
| [37] |
Li J. Targeting claudins in cancer: diagnosis, prognosis and therapy[J]. Am J Cancer Res, 2021, 11(7):3406-3424.
|
)
